SCHEMBL3080925

SCHEMBL3080925

C(=NN=Cc1cccc2ccccc12)c1cccc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.69
GRIN3B O60391 2/20 0.69
GRIN1 Q05586 2/20 0.69
GRIN2A Q12879 2/20 0.69
GRIN2B Q13224 2/20 0.69
GRIN2C Q14957 2/20 0.69
GRIN3A Q8TCU5 2/20 0.69
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
GCGR P47871 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
POLB P06746 3/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11342221 1.00 GRIN2D (0.69) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30427622 1.00 GRIN2D (0.69) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL17560810 0.82 GRIN2D (1.00) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL17560814 0.82 GRIN2D (1.00) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3075745 0.82 CRHBP (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3061463 0.82 CRHBP (0.82) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3074290 0.82 GRIN2D (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31182408 0.82 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL533800 0.82 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2649534 0.82 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124919-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-12-02 EP claimed
US-20080318987-A1 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 US claimed
WO-2008103314-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-08-28 WO claimed
US-4655845-A Process for preparing organic pigments having excellent application properties HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-07 US claimed
EP-0173927-A2 Process for the manufacture of organic pigments with prominent technical application properties HOECHST AKTIENGESELLSCHAFT (DE) 1986-03-12 EP claimed
EP-0075182-B1 CONDITIONING PROCESS OF AN ORGANIC PIGMENT Mobay Chemical Corporation (US) 1985-12-11 EP claimed
EP-0069895-B1 PROCESS FOR CONDITIONING A PIGMENT Mobay Chemical Corporation (US) 1984-10-10 EP claimed
EP-0075182-A1 Conditioning process of an organic pigment Mobay Chemical Corporation (US) 1983-03-30 EP claimed
EP-0069895-A2 Process for conditioning a pigment Mobay Chemical Corporation (US) 1983-01-19 EP claimed
US-4268603-A Photoresist compositions TOKYO OHKA KOGYO KABUSHIKI KAISHA (JP) 1981-05-19 US claimed
US-20260143906-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-05-21 US disclosed
EP-4530319-A1 C.I. PIGMENT YELLOW 101, METHOD FOR PRODUCING THE SAME, AND COLORING COMPOSITION CONTAINING C.I. PIGMENT YELLOW 101 FUJIFILM Business Innovation Corp. (JP) 2025-04-02 EP disclosed
CN-119708876-A C.i. pigment yellow 101, process for producing the same, and coloring composition containing c.i. pigment yellow 101 富士胶片商业创新有限公司 2025-03-28 CN disclosed
US-20250101232-A1 C.I. PIGMENT YELLOW 101, METHOD FOR PRODUCING THE SAME, AND COLORING COMPOSITION CONTAINING C.I. PIGMENT YELLOW 101 FUJIFILM BUSINESS INNOVATION CORP. (JP) 2025-03-27 US disclosed
WO-2021121294-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2021-06-24 WO disclosed
EP-0069895-A2 Process for conditioning a pigment Mobay Chemical Corporation (US) 1983-01-19 EP disclosed
EP-0044474-A2 Pigment preparations, process for their manufacture and their use BAYER AG (DE) 1982-01-27 EP disclosed
US-4268603-A Photoresist compositions TOKYO OHKA KOGYO KABUSHIKI KAISHA (JP) 1981-05-19 US disclosed
US-4082838-A PROCESS FOR PREPARING HYDRAZINE PURSLEY JOHN A 1978-04-04 US disclosed
US-3939147-A Novel 1,2-diaza-1,5,9-cyclo dodecatrienes and 1,2-diaza-1-cyclododecenes CIBA-GEIGY CORPORATION (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260143906-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OXSR1, CBR1 GRIN2D 129/4885GRIN3B 1310/4885GRIN1 186/4885
US-20080318987-A1 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION BMP4, BMP2, SOST GRIN2D 3657/4885GRIN3B 2773/4885GRIN1 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.